What is Algorithmic Biologics?
Founded in 2020, Algorithmic Biologics operates at the intersection of molecular biology and computational science. Based in Bengaluru, the company specializes in the development of advanced molecular technologies designed to address complex biological challenges. By integrating algorithmic precision with biological research, the firm provides high-value solutions that enhance diagnostic accuracy and research efficiency. Its market position is defined by a commitment to deep-tech innovation, positioning it as a key player in the burgeoning Indian biotech ecosystem. The company's focus on intellectual property and scalable molecular platforms distinguishes it from traditional laboratory service providers, allowing for a more agile and data-centric approach to life sciences.
How much funding has Algorithmic Biologics raised?
Algorithmic Biologics has raised a total of $2.5M across 1 funding round:
Series A
$2.5M
Series A (2024): $2.5M with participation from Bharat Innovation Fund and Axilor Ventures
Key Investors in Algorithmic Biologics
Bharat Innovation Fund
Bharath Innovation Fund is a venture capital and private equity firm focusing on early-stage, deep-tech and intellectual property venture funds.
Axilor Ventures
Axilor Ventures is a platform for supporting early-stage startups through accelerator and seed fund programs, founded by prominent business leaders.
What's next for Algorithmic Biologics?
With the successful closure of this major enterprise-level funding, Algorithmic Biologics is expected to prioritize the expansion of its research and development capabilities. The strategic roadmap likely includes the scaling of its proprietary molecular platforms and the pursuit of broader market penetration within the global life sciences sector. As the company matures, the focus will shift toward commercializing its core technologies and establishing strategic partnerships that leverage its unique computational biology expertise. Investors will be closely monitoring the firm's ability to translate its technological advancements into sustainable revenue streams, particularly as it navigates the competitive landscape of molecular diagnostics and biotechnology innovation. The current capital structure provides the necessary runway to achieve these ambitious growth objectives while maintaining a competitive edge in the deep-tech domain.
See full Algorithmic Biologics company page
